Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Nov 3 - Nov 8
Ozempic and Mounjaro are approved for the treatment of Type 2 diabetes, while Wegovy and Zepbound are approved for weight management in adults with obesity or who are overweight
Another study observed weight loss of 5.9% at three months and 10.9% at six months
Lilly has said they plan to submit the drug to the FDA for type 2 diabetes approval sometime in 2026
Cigna's $200/Month Cap Program In 2025, Cigna's Evernorth division announced a program that caps out-of-pocket costs for Wegovy and Zepbound at $200 per month on some employer-sponsored plans
US$ 26.96
US$ 26.65
US$ 25.03
US$ 25.54
US$ 25.81
